EZVIZ DL50FVS named Export Product of the Year at the 2025 Asian Export Awards for its self-manufactured reliability and next-generation accessibility 19-11-2025, 17:01

Io Therapeutics, Inc., presented data from studies of IRX4204, the company’s phase II clinical development stage, highly selective third generation RXR nuclear receptor agonist compound, supporting its potential use for prevention and treatment of normal 10-07-2024, 07:00

Banle Group to report 2023 financial results and host Investor Webinar 9-04-2024, 20:16